{"id":1013923,"date":"2026-10-27T07:35:49","date_gmt":"2026-10-27T11:35:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/"},"modified":"2026-10-27T07:35:49","modified_gmt":"2026-10-27T11:35:49","slug":"inflarx-announces-november-investor-events","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/","title":{"rendered":"InflaRx Announces November Investor Events"},"content":{"rendered":"
\n

\n Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) — <\/b>InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.<\/p>\n

\n Guggenheim Securities 3rd Annual Healthcare Innovation Conference
<\/b>November 9 \u2013 11, 2026 in Boston, MA
Fireside chat on November 10 at 9:30 AM EST
InflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and its replay is available\u00a0here<\/a>.<\/p>\n

\n Jefferies Global Healthcare Conference
<\/b>November 16 \u2013 19, 2026 in London, UK
One-on-one investor meetings
Jefferies will organize one-on-one investor meetings with InflaRx on November 16th<\/sup> and 17th<\/sup>.<\/p>\n

\n Third quarter 2026 earnings and operating results<\/b>\n <\/p>\n

The Company will report its third quarter 2026 financial and operating results on November 3<\/b>, 2026<\/b>, before the market opens, via a Form 6-K with the U.S. Securities and Exchange Commission (SEC). An update regarding quarterly results will be included during the Capital Markets Day.<\/p>\n

\n Capital Markets Day<\/b>\n <\/p>\n

As previously announced, InflaRx will host a virtual Capital Markets Event on November\u00a03, 2026<\/b>, from 8:00 AM EST \/ 2:00 PM CET to approximately 9:00 AM EST \/ 3:00 PM CET. Featuring leading experts in the fields of ANCA-associated vasculitis (AAV) and complement inhibition, the event will provide an overview of the evolving treatment landscape and unmet need in AAV, and how izicopan\u2019s differentiated chemistry, metabolic properties, and potential safety advantages could improve upon the existing standard of care in AAV.<\/p>\n

The event will also provide updated thinking on InflaRx\u2019s development strategy in AAV, including an overview of the anticipated clinical program. The event will feature presentations from members of InflaRx\u2019s management team and invited external experts, followed by a question-and-answer session. To participate in the virtual event, participants are requested to pre-register here<\/a> to receive an invite link and dial-in details to access the event.<\/p>\n

\n
\n About InflaRx<\/i>
\n <\/b>
\n
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx\u2018s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK\/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.<\/p>\n

InflaRx and the group have offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de<\/u><\/a>. Follow InflaRx on LinkedIn<\/u><\/a>. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).<\/p>\n

\n
\n Contacts:<\/i>
\n <\/b>\n <\/p>\n\n\n\n\n
\n InflaRx N.V.<\/b>\n <\/td>\n\n MC Services AG<\/b>\n <\/td>\n<\/tr>\n
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de<\/u><\/a><\/td>\n		Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu<\/u><\/a>
Europe: +49 89-210 2280
U.S.: +1-339-832-0752<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n FORWARD-LOOKING STATEMENTS<\/b>\n <\/p>\n

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cbelieve,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue,\u201d among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading \u201cRisk Factors\u201d and \u201cCautionary statement regarding forward looking statements\u201d in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 \u2013 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and its replay is available\u00a0here. Jefferies Global Healthcare ConferenceNovember 16 \u2013 19, 2026 in London, UKOne-on-one investor meetingsJefferies will organize one-on-one investor meetings with InflaRx on November 16th and 17th. Third quarter 2026 earnings and operating results The Company will report its third quarter 2026 financial and operating results on … <\/p>\n

Continue reading “InflaRx Announces November Investor Events”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1013923","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nInflaRx Announces November Investor Events - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InflaRx Announces November Investor Events - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 \u2013 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and its replay is available\u00a0here. Jefferies Global Healthcare ConferenceNovember 16 \u2013 19, 2026 in London, UKOne-on-one investor meetingsJefferies will organize one-on-one investor meetings with InflaRx on November 16th and 17th. Third quarter 2026 earnings and operating results The Company will report its third quarter 2026 financial and operating results on … Continue reading "InflaRx Announces November Investor Events"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T11:35:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InflaRx Announces November Investor Events\",\"datePublished\":\"2026-10-27T11:35:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/\"},\"wordCount\":713,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/\",\"name\":\"InflaRx Announces November Investor Events - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=\",\"datePublished\":\"2026-10-27T11:35:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inflarx-announces-november-investor-events\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InflaRx Announces November Investor Events\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InflaRx Announces November Investor Events - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/","og_locale":"en_US","og_type":"article","og_title":"InflaRx Announces November Investor Events - Market Newsdesk","og_description":"Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation ConferenceNovember 9 \u2013 11, 2026 in Boston, MAFireside chat on November 10 at 9:30 AM ESTInflaRx will also conduct one-on-one investor meetings on November 10th. A link to view the fireside chat live stream and its replay is available\u00a0here. Jefferies Global Healthcare ConferenceNovember 16 \u2013 19, 2026 in London, UKOne-on-one investor meetingsJefferies will organize one-on-one investor meetings with InflaRx on November 16th and 17th. Third quarter 2026 earnings and operating results The Company will report its third quarter 2026 financial and operating results on … Continue reading \"InflaRx Announces November Investor Events\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-27T11:35:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InflaRx Announces November Investor Events","datePublished":"2026-10-27T11:35:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/"},"wordCount":713,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/","name":"InflaRx Announces November Investor Events - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=","datePublished":"2026-10-27T11:35:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1Mzg5NCM3OTE4MzQ4IzIxOTQyNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inflarx-announces-november-investor-events\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InflaRx Announces November Investor Events"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1013923"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1013923\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1013923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1013923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1013923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}